Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Rafat Abonour, Lynne Wagner, Brian G.M. Durie, Sundar Jagannath, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Amani Kitali, Craig J. Gibson, Shankar Srinivasan, Arlene S. Swern, Robert M. Rifkin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients’ HRQoL. Additional research is needed to verify these findings.

Original languageEnglish (US)
JournalAnnals of Hematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Multiple Myeloma
Registries
Transplantation
Maintenance
Quality of Life
Stem Cell Transplantation
Therapeutics
Pain
Equipment and Supplies
Neoplasms
Disease Progression
lenalidomide

Keywords

  • Community medicine
  • Multiple myeloma
  • Quality of life
  • Registry
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma : data from the Connect® MM Registry. / Abonour, Rafat; Wagner, Lynne; Durie, Brian G.M.; Jagannath, Sundar; Narang, Mohit; Terebelo, Howard R.; Gasparetto, Cristina J.; Toomey, Kathleen; Hardin, James W.; Kitali, Amani; Gibson, Craig J.; Srinivasan, Shankar; Swern, Arlene S.; Rifkin, Robert M.

In: Annals of Hematology, 01.01.2018.

Research output: Contribution to journalArticle

Abonour, R, Wagner, L, Durie, BGM, Jagannath, S, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Kitali, A, Gibson, CJ, Srinivasan, S, Swern, AS & Rifkin, RM 2018, 'Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry', Annals of Hematology. https://doi.org/10.1007/s00277-018-3446-y
Abonour, Rafat ; Wagner, Lynne ; Durie, Brian G.M. ; Jagannath, Sundar ; Narang, Mohit ; Terebelo, Howard R. ; Gasparetto, Cristina J. ; Toomey, Kathleen ; Hardin, James W. ; Kitali, Amani ; Gibson, Craig J. ; Srinivasan, Shankar ; Swern, Arlene S. ; Rifkin, Robert M. / Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma : data from the Connect® MM Registry. In: Annals of Hematology. 2018.
@article{6973e297de374fa4a2540b9d96d92ae4,
title = "Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect{\circledR} MM Registry",
abstract = "Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients’ HRQoL. Additional research is needed to verify these findings.",
keywords = "Community medicine, Multiple myeloma, Quality of life, Registry, Stem cell transplantation",
author = "Rafat Abonour and Lynne Wagner and Durie, {Brian G.M.} and Sundar Jagannath and Mohit Narang and Terebelo, {Howard R.} and Gasparetto, {Cristina J.} and Kathleen Toomey and Hardin, {James W.} and Amani Kitali and Gibson, {Craig J.} and Shankar Srinivasan and Swern, {Arlene S.} and Rifkin, {Robert M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00277-018-3446-y",
language = "English (US)",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma

T2 - data from the Connect® MM Registry

AU - Abonour, Rafat

AU - Wagner, Lynne

AU - Durie, Brian G.M.

AU - Jagannath, Sundar

AU - Narang, Mohit

AU - Terebelo, Howard R.

AU - Gasparetto, Cristina J.

AU - Toomey, Kathleen

AU - Hardin, James W.

AU - Kitali, Amani

AU - Gibson, Craig J.

AU - Srinivasan, Shankar

AU - Swern, Arlene S.

AU - Rifkin, Robert M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients’ HRQoL. Additional research is needed to verify these findings.

AB - Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients’ HRQoL. Additional research is needed to verify these findings.

KW - Community medicine

KW - Multiple myeloma

KW - Quality of life

KW - Registry

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85050950585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050950585&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3446-y

DO - 10.1007/s00277-018-3446-y

M3 - Article

C2 - 30056582

AN - SCOPUS:85050950585

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -